Teva Pharmaceutical Industries Limited rose 2.18% in premarket trading. The company reported a Q2 profit that exceeded estimates, driven by gains in branded drugs. Additionally, Teva's innovative portfolio has fueled its 10th consecutive quarter of growth, indicating strong performance and potential for future success.
Comments
No comments yet